Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Tenofovir generic patent?
Brenzavvy discontinuation?
Mebendazole ingredients?
Xiaflex market launch year?
Dabrafenib and trametinib cost?

Vraylar indications for use?

See the DrugPatentWatch profile for Vraylar

What is Vraylar (cariprazine) approved for?

Vraylar (cariprazine) is approved to treat certain psychiatric conditions, including schizophrenia in adults. [1]

It is also approved for:
- Bipolar I disorder—depressive episodes in adults, and manic or mixed episodes in adults. [1]
- Bipolar I disorder—manic or mixed episodes in pediatric patients ages 10 years and older. [1]

Which Vraylar “indications” cover depression vs mania?

Vraylar’s labeled bipolar uses include both mood phases:
- Bipolar I disorder depressive episodes: indicated for adults. [1]
- Bipolar I disorder manic or mixed episodes: indicated for adults, and also for pediatric patients ages 10+ for manic or mixed episodes. [1]

Are the indications the same for adults and children?

No. The pediatric indication is limited to manic or mixed episodes of bipolar I disorder for ages 10 years and older. Schizophrenia and bipolar depression indications are for adults. [1]

What exactly does “indicated for” mean for clinicians and patients?

“Indicated for” means the specific condition(s), age group(s), and disease phase(s) (for example, depressive vs manic/mixed) that the drug’s labeling supports. For Vraylar, the labeled conditions are schizophrenia (adults) and bipolar I disorder (depression in adults; manic/mixed in adults and ages 10+). [1]

Sources

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207422



Other Questions About Vraylar :

Abbvie vraylar loss of exclusivity or patent expiration date? Vraylar spending money? Vraylar cost goodrx? Vraylar price? Vraylar generic availability? Vraylar discount? Vraylar copay assistance?

AI-Drug Label Prescribing Information Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated claim regarding schizophrenia treatment in adults and pediatric patients aged 13 years and older is directly supported by the provided FDA label sections.

Category Scores

Indication
100
Excellent

Accurate Statements

VRAYLAR is indicated for treatment of schizophrenia in adult and pediatric patients 13 years of age and older.
INDICATIONS AND USAGE: 'Treatment of schizophrenia in adult and pediatric patients 13 years of age and older'; 8.4 Pediatric Use: 'The safety and effectiveness of VRAYLAR for treatment of schizophrenia have been established in pediatric patients 13 years of age and older.'

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The claim is an on-label indication and age range; no dosing or safety assertions were made in the evaluated response.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Only one of several user-provided claims was evaluated in the provided AI response; the other claims (bipolar depression, bipolar manic/mixed, and related pediatric age limits) were not assessed here.

Suggested Improvement
Evaluate each claim against the corresponding 'Indications and Usage' and 'Pediatric Use' label wording, including pediatric age thresholds and whether the indication is for adults only.

Drug Brand Mention Assessment

Branding Score
50
Visibility
51
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

schizophrenia (adults) and bipolar I disorder (depression in adults; manic/mixed in adults and ages 10+).

Core Claims
  • Vraylar (cariprazine) is approved to treat certain psychiatric conditions, including schizophrenia in adults.
  • Vraylar is also approved for bipolar I disorder—depressive episodes in adults, and manic or mixed episodes in adults.
  • Vraylar is approved for bipolar I disorder—manic or mixed episodes in pediatric patients ages 10 years and older.
Differentiators
  • Pediatric indication is limited to manic or mixed episodes of bipolar I disorder for ages 10+.
  • Schizophrenia and bipolar depression indications are for adults.
Pricing Perception: Not Mentioned